Hyderabad News Desk

The Attention Deficit Hyperactivity Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Attention Deficit Hyperactivity Disorder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Attention Deficit Hyperactivity Disorder Market.

Some of the key takeaways from the Attention Deficit Hyperactivity Disorder Pipeline Report:

• Companies across the globe are diligently working toward developing novel Attention Deficit Hyperactivity Disorder treatment therapies with a considerable amount of success over the years. 
• Attention Deficit Hyperactivity Disorder companies working in the treatment market are Afecta Pharmaceuticals, ABVC BioPharma, Mind Medicine, Neurocentria, Cingulate Therapeutics, Otsuka Pharmaceutical, Cortex Pharmaceuticals, and others, are developing therapies for the Attention Deficit Hyperactivity Disorder treatment 
• Emerging Attention Deficit Hyperactivity Disorder therapies in the different phases of clinical trials are- AFX-2401, PDC-1421, MM-120, NRCT-101SR, CTx-1301, Centanafadine, CX717, and others are expected to have a significant impact on the Attention Deficit Hyperactivity Disorder market in the coming years.   
• In March 2023, Following approval from the US Food and Drug Administration (FDA), Cingulate and Indegene announced a collaborative commercialization agreement to provide commercial assistance for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate) for attention-deficit/hyperactivity disorder (ADHD). In order to successfully handle pre-commercial support during Cingulate’s Phase 3 clinical trials and to efficiently commercialise CTx-1301 across the country following probable FDA approval, the agreement encompasses cross-functional services through an omnichannel marketing approach.
• In February 2023, With the signing of a new licencing agreement with US-based biopharmaceutical business Axsome Therapeutics, Inc., Pharmanovia announced the extension of their neurology product line. The agreement enables Pharmanovia to investigate the potential of solriamfetol in treating various neurological diseases, such as attention deficit hyperactivity disorder (ADHD), and grants Pharmanovia the exclusive marketing rights to Sunosi (solriamfetol).
• In February 2023, Top-line results from the CTx-1301-003 research, which examined how food affects the absorption of its lead candidate CTx-1301, were favourable, according to Cingulate. Dexmethylphenidate, a drug licenced by the US Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD), has been reformulated into a unique, investigational, trimodal, extended-release tablet. CTx-1301 can be taken with or without food, according to the experiment. A favourable tolerability profile was indicated by adverse events that were consistent with prior findings across many pharmacokinetic (PK) parameters.
• In January 2023, NLS Pharmaceutics Ltd. reported that Patent Application 42022055879.5, which covers Mazindol ER as a method of treating ADHD, has been approved by the Patents Registry, Intellectual Property Department of The Government of the Hong Kong Special Administrative Region. The projected expiration date of this patent is 2037 at the latest.
• In January 2023, At the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session, Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, will present the findings of the Phase IIa study of ABVC BioPharma’s medication, ABV-1505 ADHD. Six adults with diagnosed ADHD participated in the Phase IIa research, which used PDC-1421, the active pharmacological ingredient of ABV-1505. PDC-1421 was shown to be safe, well-tolerated, and effective during the therapy and the follow-up period at low and high doses, according to the study.
• In October 2022, The signing of a Master Services Agreement (MSA) between Cingulate and Societal CDMO was announced. Societal CDMO will produce all clinical, registration, and commercial batches of Cingulate’s lead candidate CTx-1301, an investigational drug for the management of Attention Deficit/Hyperactivity Disorder (ADHD). Societal CDMO’s capabilities range from pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms. Within its plant in Gainesville, Georgia, Societal CDMO will designate a particular manufacturing suite and furnish it with specialised equipment provided by Cingulate.

Attention Deficit Hyperactivity Disorder Overview

The ability of children to function is impacted by the psychiatric disorder Attention Deficit-Hyperactivity Disorder (ADHD). People with this illness exhibit tendencies of inattentiveness, hyperactivity, or impulsivity that are developmentally inappropriate.

Get a Free Sample PDF Report to know more about Attention Deficit Hyperactivity Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-pipeline-insight

Emerging Attention Deficit Hyperactivity Disorder Drugs Under Different Phases of Clinical Development Include:

• AFX-2401: Afecta Pharmaceuticals
• PDC-1421: ABVC BioPharma
• MM-120: Mind Medicine
• NRCT-101SR: Neurocentria
• CTx-1301: Cingulate Therapeutics
• Centanafadine: Otsuka Pharmaceutical
• CX717: Cortex Pharmaceuticals

Attention Deficit Hyperactivity Disorder Route of Administration

Attention Deficit Hyperactivity Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Attention Deficit Hyperactivity Disorder Molecule Type

Attention Deficit Hyperactivity Disorder Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Attention Deficit Hyperactivity Disorder Pipeline Therapeutics Assessment

• Attention Deficit Hyperactivity Disorder Assessment by Product Type
• Attention Deficit Hyperactivity Disorder By Stage and Product Type
• Attention Deficit Hyperactivity Disorder Assessment by Route of Administration
• Attention Deficit Hyperactivity Disorder By Stage and Route of Administration
• Attention Deficit Hyperactivity Disorder Assessment by Molecule Type
• Attention Deficit Hyperactivity Disorder by Stage and Molecule Type

DelveInsight’s Attention Deficit Hyperactivity Disorder Report covers around 22+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Attention Deficit Hyperactivity Disorder product details are provided in the report. Download the Attention Deficit Hyperactivity Disorder pipeline report to learn more about the emerging Attention Deficit Hyperactivity Disorder therapies

Some of the key companies in the Attention Deficit Hyperactivity Disorder Therapeutics Market include:

Key companies developing therapies for Attention Deficit Hyperactivity Disorder are – Cingulate Therapeutics, Otsuka Pharmaceutical, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, NLS Pharmaceutics, 3Z Pharmaceuticals, and others.

Attention Deficit Hyperactivity Disorder Pipeline Analysis:

The Attention Deficit Hyperactivity Disorder pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Attention Deficit Hyperactivity Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Attention Deficit Hyperactivity Disorder Treatment.
• Attention Deficit Hyperactivity Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Attention Deficit Hyperactivity Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Attention Deficit Hyperactivity Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Attention Deficit Hyperactivity Disorder drugs and therapies

Attention Deficit Hyperactivity Disorder Pipeline Market Drivers

• Increasing Prevalence of Attentiondeficit/hyperactivity disorder, increase in research and developmental activities are some of the important factors that are fueling the Attention Deficit Hyperactivity Disorder Market.

Attention Deficit Hyperactivity Disorder Pipeline Market Barriers

• However, side-effects associated with the treatment of Attention deficit/hyperactivity disorder, challenges in terms of the diagnosis of ADHD and other factors are creating obstacles in the Attention Deficit Hyperactivity Disorder Market growth.

Scope of Attention Deficit Hyperactivity Disorder Pipeline Drug Insight    

• Coverage: Global
• Key Attention Deficit Hyperactivity Disorder Companies: Afecta Pharmaceuticals, ABVC BioPharma, Mind Medicine, Neurocentria, Cingulate Therapeutics, Otsuka Pharmaceutical, Cortex Pharmaceuticals, and others
• Key Attention Deficit Hyperactivity Disorder Therapies: AFX-2401, PDC-1421, MM-120, NRCT-101SR, CTx-1301, Centanafadine, CX717, and others
• Attention Deficit Hyperactivity Disorder Therapeutic Assessment: Attention Deficit Hyperactivity Disorder current marketed and Attention Deficit Hyperactivity Disorder emerging therapies
• Attention Deficit Hyperactivity Disorder Market Dynamics: Attention Deficit Hyperactivity Disorder market drivers and Attention Deficit Hyperactivity Disorder market barriers 

Request for Sample PDF Report for Attention Deficit Hyperactivity Disorder Pipeline Assessment and clinical trials

Table of Contents 

1. Attention Deficit Hyperactivity Disorder Report Introduction

2. Attention Deficit Hyperactivity Disorder Executive Summary

3. Attention Deficit Hyperactivity Disorder Overview

4. Attention Deficit Hyperactivity Disorder- Analytical Perspective In-depth Commercial Assessment

5. Attention Deficit Hyperactivity Disorder Pipeline Therapeutics

6. Attention Deficit Hyperactivity Disorder Late Stage Products (Phase II/III)

7. Attention Deficit Hyperactivity Disorder Mid Stage Products (Phase II)

8. Attention Deficit Hyperactivity Disorder Early Stage Products (Phase I)

9. Attention Deficit Hyperactivity Disorder Preclinical Stage Products

10. Attention Deficit Hyperactivity Disorder Therapeutics Assessment

11. Attention Deficit Hyperactivity Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Attention Deficit Hyperactivity Disorder Key Companies

14. Attention Deficit Hyperactivity Disorder Key Products

15. Attention Deficit Hyperactivity Disorder Unmet Needs

16 . Attention Deficit Hyperactivity Disorder Market Drivers and Barriers

17. Attention Deficit Hyperactivity Disorder Future Perspectives and Conclusion

18. Attention Deficit Hyperactivity Disorder Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services